In:
Cancer, Wiley, Vol. 120, No. 24 ( 2014-12-15), p. 3896-3901
Abstract:
Using a new method that allows for the quantification of the level of tumor DNA with epidermal growth factor receptor (EGFR) mutations in a blood sample, the authors were able to monitor the effect of the EGFR‐targeting agent erlotinib in patients with lung cancer. Most interestingly, the results of the current study demonstrate that a mutation (T790M) causing erlotinib resistance can be detected in the blood up to 1 year earlier than disease progression can be identified by Response Evaluation Criteria In Solid Tumors (RECIST) criteria.
Type of Medium:
Online Resource
ISSN:
0008-543X
,
1097-0142
DOI:
10.1002/cncr.v120.24
Language:
English
Publisher:
Wiley
Publication Date:
2014
detail.hit.zdb_id:
1479932-7
detail.hit.zdb_id:
2599218-1
detail.hit.zdb_id:
2594979-2
detail.hit.zdb_id:
1429-1
Permalink